Meeting
2018 ASCO Annual Meeting
A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma.
Authors
Nehal J. Lakhani
START Midwest, Grand Rapids, MI
Nehal J. Lakhani , Patricia LoRusso , Navid Hafez , Anuradha Krishnamurthy , Timothy J. O'Rourke , Manali K. Kamdar , Philip Fanning , Yonggang Zhao , Feng Jin , Hong Wan , Jaume Pons , Sophia Randolph , Wells A. Messersmith
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT03013218
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3068)
DOI
10.1200/JCO.2018.36.15_suppl.3068
Abstract #
3068
Poster Bd #
282
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.
First Author: Laura Quan Man Chow
Poster
2021 ASCO Annual Meeting
Phase I study of LZM005, a HER2 antibody, as monotherapy or in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.
First Author: Cong Xue
Poster
2021 ASCO Annual Meeting
A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors.
First Author: Howard A. Burris III
Poster
2020 ASCO Virtual Scientific Program
A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy.
First Author: Laura Quan Man Chow